UnknownPhase 1/2

Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza

Canada30 participantsStarted 2010-11

Plain-language summary

A Pilot Study to Evaluate the Safety and Efficacy of interferon-Alfacon1 (INFERGEN) in the treatment of patients hospitalized with Influenza-like illness caused by a novel swine origin Influenza virus and other circulating Influenza Viruses. The use of Interferon-alfacon1 as a co-treatment along with the standard of care antiviral is hypothesized to be safe. Clinical improvement of patients is hypothesized to be quicker.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Able to provide informed consent * Aged \>=18 and \< 70 * Hospitalized * suspect, probable, confirmed influenza A * symptom onset \<8 days * able to attend all scheduled visits Exclusion Criteria: * known hypersensitivity to interferon preparation * pregnancy * chronic liver disease * moderate to severe congestive heart failure, grade III or IV left ventricular function * previous history of serious psychiatric illness * history of severe or active autoimmune disease

What they're measuring

Frequency of Clinically Important (moderate or severe) and serious adverse events

Timeframe: Up to two-months post-treatment

Trial details

NCT IDNCT01227798

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-11

View on ClinicalTrials.gov More Influenza trials